21:28 , Jul 19, 2019 |  BC Extra  |  Preclinical News

July 19 Preclinical Quick Takes: Samumed's Alzheimer's candidate; plus a CRISPR RNA editing tool, new targets for fibrosis and pain

Samumed's Alzheimer's candidate reduces tau pathology, inflammation  Samumed LLC (San Diego, Calif.) reported in an Aging Cell paper that SM07883 reduced tau phosphorylation, pathological tau aggregates, neuroinflammation, weight loss and mortality in a mouse model...
15:59 , Feb 6, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer In vitro and mouse studies identified a chromenecarbaldehyde-based IRE1 inhibitor that could help treat prostate cancer. Optimization and in vitro binding assays of a family of tool compound IRE1 inhibitors yielded a...
22:41 , Jan 28, 2019 |  BC Extra  |  Preclinical News

Unfolded protein response activates MYC in prostate cancer

A European team has linked the unfolded protein response to MYC signaling, lending weight to oncology strategies targeting the IRE1/XBP1 pathway, and identified prostate cancer as another indication for XBP1 inhibitors. A U.S. team including...
18:39 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Patient sample and mouse studies suggest T cell-specific inhibition of XBP1 or IRE1 could help treat ovarian cancer. In tumor and ascites samples from patients, high T cell expression of XBP1 was...
18:33 , Oct 10, 2018 |  BC Extra  |  Preclinical News

Quentis links ER stress, mitochondrial dysfunction with antitumor T cell activity

Researchers at Quentis Therapeutics Inc. (New York, N.Y.), Weill Cornell Medicine and Dana-Farber Cancer Institute uncovered a new mechanism of tumor immune evasion in which endoplasmic reticulum stress limits mitochondrial respiration and antitumor activity in...
15:53 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting IRE1 or its RNase activity could help treat triple-negative breast cancer (TNBC). In a panel of human breast cancer cell lines, levels of IRE1 RNase...
17:42 , Mar 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; breast cancer; chronic lymphocytic leukemia (CLL); lymphoma; neuroendocrine tumors Patient sample, cell culture and mouse studies suggest inhibiting XBP1 or its activator IRE1 could help treat MYC- or MYCN-driven cancers. In breast cancer...
21:03 , Mar 2, 2018 |  BC Week In Review  |  Financial News

Quentis debuts with $48M series A

Cancer company Quentis Therapeutics Inc. (New York, N.Y.) raised $48 million on Feb. 27 in a series A round led by existing investor Versant Ventures and new investor Polaris Partners. New investors AbbVie Ventures, Taiho...
12:37 , Feb 27, 2018 |  BC Extra  |  Financial News

Quentis debuts with $48M series A

Quentis Therapeutics Inc. (New York, N.Y.) raised $48 million in a series A round led by existing investor Versant Ventures and new investor Polaris Partners. New investors AbbVie Ventures, Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan),...
12:32 , Feb 27, 2018 |  BioCentury  |  Emerging Company Profile

Stressing out cancer

Quentis Therapeutics Inc. debuted with a $48 million series A round to develop potentially first-in-class therapies that inhibit the ER stress response, with the dual effect of killing tumor cells directly and unleashing immune cells...